Rodin taps Adam Rosenberg for top post

Rodin CEO Adam Rosenberg

Cambridge, MA-based Rodin Therapeutics has recruited biotech vet Adam Rosenberg as its new CEO. Rosenberg plans to stay on as head of Teleos Therapeutics, which is in the business of doing drug discovery work for CNS diseases, until a replacement is found. Rodin is working on an HDAC2 inhibitor for Alzheimer's and other cognitive diseases. Release

Suggested Articles

Gilead Sciences is paying Nurix $45 million upfront in a deal that could reach $2.3 billion in value if all milestones are met and royalties realized.

In mice, Kymera's lead drug promoted tumor regression, both on its own and in combination with BTK inhibitor Imbruvica.

The report features testimony that some NHS bodies are “actively instructed not to deal with industry by their local leadership.”